Burning Rock Biotech (NASDAQ:BNR) Director Yusheng Han Buys 104,650 Shares of Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han purchased 104,650 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were acquired at an average price of $7.45 per share, with a total value of $779,642.50. Following the completion of the acquisition, the director owned 18,123,196 shares in the company, valued at approximately $135,017,810.20. This trade represents a 0.58% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han acquired 24,900 shares of Burning Rock Biotech stock. The stock was acquired at an average cost of $8.00 per share, for a total transaction of $199,200.00.
• On Wednesday, June 24th, Yusheng Han bought 250,000 shares of Burning Rock Biotech stock. The shares were acquired at an average price of $8.00 per share, for a total transaction of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han bought 5,990 shares of Burning Rock Biotech stock. The shares were acquired at an average price of $7.50 per share, for a total transaction of $44,925.00.
• On Tuesday, June 16th, Yusheng Han bought 111,110 shares of Burning Rock Biotech stock. The shares were acquired at an average cost of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han bought 210,000 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $9.25 per share, with a total value of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han purchased 24,760 shares of Burning Rock Biotech stock. The stock was acquired at an average cost of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Price Performance

Burning Rock Biotech stock opened at $8.96 on Thursday. The stock has a market capitalization of $94.26 million, a price-to-earnings ratio of -10.93 and a beta of 1.33. Burning Rock Biotech Limited Sponsored ADR has a 52-week low of $3.22 and a 52-week high of $41.72. The stock’s 50 day moving average price is $12.79 and its two-hundred day moving average price is $20.08. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings data on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($2.29) by $2.09. The company had revenue of $15.66 million during the quarter, compared to the consensus estimate of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Hedge Funds Weigh In On Burning Rock Biotech

A number of institutional investors have recently modified their holdings of BNR. Crcm LP lifted its holdings in shares of Burning Rock Biotech by 121.8% in the 4th quarter. Crcm LP now owns 491,426 shares of the company’s stock worth $9,902,000 after purchasing an additional 269,851 shares in the last quarter. Marshall Wace LLP acquired a new stake in Burning Rock Biotech in the 4th quarter valued at $220,000. Prospera Financial Services Inc increased its stake in Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after purchasing an additional 6,430 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Burning Rock Biotech by 13.8% in the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after acquiring an additional 4,290 shares during the last quarter. 30.03% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Wall Street Zen cut shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.